The DepoVax platform reduces the standard two to three injections of a vaccine needed for optimal immunity to just one, and it gives an earlier onset of protection, according to Immunovaccine. The firm says that in preclinical models, a single dose prevented the growth of tumors and up to 100% of cancer cells were destroyed. DepoVax works with a variety of antigens including peptides, proteins, nucleic acids, and synthetic antigens. The dry formulation can be stored and reconstituted for clinical use.
Immunovaccine says its patent protection is broad and covers combinations of any antigen, any adjuvant, and any liposome mixed with any oil. "We have a rocket booster system that enhances the immune response," says Dr. Chase, and "we can boost the immune response of any vaccine."
To prove the advantages of their platform, researchers at Immunovaccine invite other vaccine companies to take the "DepoVax challenge". Companies send their vaccines to Immunovaccine, where they are reformulated free of charge with the liposome/oil delivery system and then returned to undergo head-to-head testing.
"We believe that we can deliver other people’s products better than they can," Dr. Chase says. He notes that for many vaccines, fewer doses are required, because the DepoVax system induces a much stronger immune response. He also adds that the DepoVax challenge has led to licensing agreements on a broad range of applications.